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https://doi.org/10.1016/j.ccell.2020.03.022SUMMARYAcute erythroid leukemia (AEL) commonly involves both myeloid and erythroid lineage transformation. How-
ever, the mutations that cause AEL and the cell(s) that sustain the bilineage leukemia phenotype remain un-
known. We here show that combined biallelic Cebpa and Gata2 zinc finger-1 (ZnF1) mutations cooperatively
induce bilineage AEL, and that the major leukemia-initiating cell (LIC) population has a neutrophil-monocyte
progenitor (NMP) phenotype. In pre-leukemic NMPs Cebpa and Gata2 mutations synergize by increasing
erythroid transcription factor (TF) expression and erythroid TF chromatin access, respectively, thereby
installing ectopic erythroid potential. This erythroid-permissive chromatin conformation is retained in biline-
age LICs. These results demonstrate that synergistic transcriptional and epigenetic reprogramming by leu-
kemia-initiating mutations can generate neomorphic pre-leukemic progenitors, defining the lineage identity
of the resulting leukemia.INTRODUCTION
Acute myeloid leukemia (AML) arises through the sequential
acquisition of somatic mutations, most initially occurring in the
self-renewing hematopoietic stem cell (HSC) compartment,
and subsequently in the progenitor cells that undergo transfor-
mation (Jan et al., 2012). This leads to the pathological accumu-
lation of immature cells, arrested in differentiation, that ultimately
displace normal hematopoiesis. AML is both genetically and
morphologically heterogeneous. More than 20 genes are
commonlymutated in AML,with on average 5 such acquiredmu-Significance
Wehere show that, together,Cebpa andGata2mutations can c
cellularly and molecularly analogous to human AEL. We also
gating cells that remain bipotent at the single-cell level, and th
we identify a mechanism whereby transcriptional and epigenet
tively, synergize to define the lineage identity of the resulting le
lecular framework for the etiology of, and provide a pre-clinical
studying the pre-leukemic state for understanding oncogene c
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This is an open access article under the CC BY license (http://creativetations observed in each tumor (Cancer GenomeAtlas Research,
2013), giving rise to monocytic, neutrophil, erythroid, and mega-
karyocytic (Bennett et al., 1976), and more rarely basophil/mast
cell and eosinophil leukemia (Lichtman and Segel, 2005).
Gene expression profiling identified 16 transcriptional AML
subtypes, many correlated with specific driver mutations,
including FLT3, RUNX1, CEBPA, and MLL1 mutations (Valk
et al., 2004). Furthermore, 11 distinct mutational patterns
were observed (Papaemmanuil et al., 2016), including associ-
ation of NPM1 mutation with mutations involved in DNA
methylation, and RUNX1 and CBFB translocations with KITause bilineage AEL inmice, and that the resulting leukemia is
show AEL is maintained by self-renewing leukemia-propa-
us generate a bilineage differentiation hierarchy. In addition,
ic changes, induced by Cebpa and Gata2mutation, respec-
ukemia. Together, these findings generate a cellular and mo-
model for, bilineage AEL, and underscore the importance of
ollaboration during leukemogenesis.
blished by Elsevier Inc.
commons.org/licenses/by/4.0/).
ll
Articleand NRAS mutation. In addition, specific association of
CEBPA mutation with GATA2 zinc finger-1 (ZnF1) mutation,
distinct from the GATA2 ZnF2 mutations associated with
MonoMAC syndrome (Hsu et al., 2011), was observed (Metz-
eler et al., 2016; Papaemmanuil et al., 2016), whereas other
common mutations (FLT3-ITD, NPM1, MLL, RUNX1, and
IDH1/2) were negatively correlated to biallelic CEBPA muta-
tion (Fasan et al., 2014). Targeted sequencing confirmed the
prevalence of GATA2 ZnF1 mutations in CEBPA mutant
AML, with additional common mutations observed only in a
minority (6/35) of patients (Fasan et al., 2013; Greif et al.,
2012; Ping et al., 2017). Interestingly, while the majority of pa-
tients carrying GATA2 mutations were of a granulocytic (M1 or
M2) subtype, mutations were also observed in acute erythroid
leukemia (AEL) (AML M6 subtype) (Fasan et al., 2013). In AEL
there was a specific and statistically significant association of
biallelic CEBPA mutation to GATA2 ZnF1 mutation, as well as
a higher incidence of GATA2 ZnF1 mutation compared with
non-AEL AML (Ping et al., 2017).
This indicated that combined CEBPA and GATA2 mutations
contribute to the etiology of both myeloblastic and erythroid
acute leukemias. AEL in its most common form is bilineage,
characterized by the presence of both myeloblasts (MBs) and
erythroblasts blocked in their differentiation (Arber et al.,
2008; Zuo et al., 2010). However, while several studies have
identified recurrent mutations in AEL tumors (Cervera et al.,
2016; Ping et al., 2017; Santos et al., 2009), and erythroid line-
age transformation has been successfully modeled (Iacobucci
et al., 2019; Thoene et al., 2019), so far no mutations have
been identified as causative of bilineage AEL. M1 and M2
AML subtypes, which are also those principally observed to
contain biallelic CEBPAmutations (Valk et al., 2004), are gener-
ated by transformation of the neutrophil granulocyte lineage.
Murine studies have shown that neutrophil differentiation pro-
gresses via progenitors committed to a neutrophil/monocyte
fate (neutrophil-monocyte progenitors or NMPs), where Gata2
expression is low or absent (Drissen et al., 2016). Conversely,
erythroid lineage progenitors express high levels of Gata2,
but lack Cebpa expression (Pronk et al., 2007). This raises the
question of how, and in which cell type, synergy between
CEBPA and GATA2 mutations is achieved, and in particular
whether the bilineage leukemia phenotype is maintained by a
single bipotent, or by two distinct lineage-restricted, leuke-
mia-propagating cell populations.
Two types of CEBPA mutations are observed in AML: N-ter-
minal mutations leading to selective loss of the C/EBPa
42 kDa isoform (p42) while preserving translation of the 30-
kDa isoform (p30), and C-terminal mutations that disable DNA
binding of both C/EBPa p42 and p30, while preserving the
leucine zipper dimerization domain. Both types of mutations
impair the ability of C/EBPa to block cell-cycle progression
via E2F repression (Lopez et al., 2009). Patients with biallelic
CEBPA mutation most commonly carry one mutation of each
type (Nerlov, 2004; Wouters et al., 2009). We have previously
modeled biallelic CEBPA mutant AML in the mouse and
observed that the combination of N- and C-terminal C/EBPa
mutation is optimal for leukemogenesis (Bereshchenko et al.,
2009), consistent with the clinically observed mutation pattern.
This combination of Cebpa mutations both decreases HSCquiescence, leading to expansion of pre-malignant HSCs,
and allows myeloid lineage commitment (Bereshchenko et al.,
2009). Myeloid lineage commitment is important for leukemo-
genesis, as Cebpa mutant leukemias are propagated by
committed myeloid progenitors (Bereshchenko et al., 2009;
Kirstetter et al., 2008) whose self-renewal is dramatically
increased by loss of C/EBPa-mediated E2F repression (Porse
et al., 2005), and requires the p30 isoform, which retains the
SWI/SNF binding domain critical for activation of C/EBP-
dependent myeloid lineage genes (Pedersen et al., 2001). Com-
plete loss of C/EBPa consequently does not induce AML due to
lack of granulocyte-monocyte progenitor formation (Zhang
et al., 2004).
In contrast little is known about the role of GATA2 ZnF1 muta-
tions in myeloid leukemogenesis. GATA-2 ZnF1 is known to
interact with other transcription factors (TFs), including FOG-1
(Chang et al., 2002) and LMO2 (Osada et al., 1995). However,
the ZnF1 residues mutated in AML (Fasan et al., 2013; Greif
et al., 2012; Papaemmanuil et al., 2016; Ping et al., 2017) do
not correspond to those that interact with FOG-1 or LMO2 (Wil-
kinson-White et al., 2011). The molecular and cellular conse-
quences of GATA2 ZnF1 mutations therefore still need to be
identified, and so far no genetic model of this mutation has
been generated.
To understand the role of GATA2 ZnF1 mutations in myeloid
leukemogenesis, and to model human bilineage AEL, we there-
fore generated a murine genetic model of combined biallelic
CEBPA and GATA2 ZnF1 mutation.
RESULTS
Generation of an Accurate Model of Combined CEBPA
and GATA2 Mutant AML
To model combined CEBPA and GATA2 ZnF1 mutations we
generated a murine germ line knock-in allele of the human
GATA2 G320D mutation (henceforth Gata2D allele) that was
observed in conjunction with biallelic CEBPA mutation in mul-
tiple studies (Fasan et al., 2013; Greif et al., 2012; Papaemma-
nuil et al., 2016; Ping et al., 2017) (Figure S1A). GATA2 ZnF1
mutations are heterozygous (Greif et al., 2012), and consistent
with this we observed that homozygosity, but not heterozy-
gosity, for the Gata2D allele led to loss of HSC self-renewal
(Figures S1B–S1E). We therefore combined a single Gata2D
allele with the previously described N- and C-terminal Cebpa
knock-in mutations (CebpaL [Kirstetter et al., 2008] and Ceb-
paK alleles [Bereshchenko et al., 2009], respectively) to
generate triple knock-in mice carrying biallelic Cebpa and
heterozygous Gata2 ZnF1 mutation (CebpaK/L; Gata2D/+ or
KLG genotype), as well as CebpaK/L (KL genotype) and Ga-
ta2D/+ (G genotype) mice. Because of the perinatal lethality
of the CebpaK/L mutation we generated embryonic day 14.5
fetal liver (FL) cells with these genotypes, and wild-type (WT)
control FLs (CD45.2 allotype). These were competitively
transplanted into lethally irradiated recipients (CD45.1/2
allotype) using CD45.1/2 WT competitor, as described previ-
ously (Bereshchenko et al., 2009) (Figure S2A). Where indi-
cated the CD45.1/2 allotype was combined with the Gata1-
EGFP transgene that efficiently labels platelets and erythroid
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Figure 1. Biallelic Cebpa and Gata2 ZnF1
Mutations Synergistically Induce Erythroid
Leukemia
(A) Event-free survival. Differences in survival were
analyzed using a Mantel-Cox log-rank test.
(B) White blood cell count in mice from (A). Pa-
rameters were measured during terminal analysis.
Leukemic mice were analyzed when moribund,
non-leukemic mice at 52 weeks post-trans-
plantation. WT, n = 7; G, n = 9; KL, n = 13; KLG, n =
23 in four independent experiments. The mean
and significant differences between genotypes are
indicated.
(C) Red blood cell (RBC) count in mice from (A).
(D) Platelet count in mice from (A).
(E) Spleen weight in mice from (A).
(F) Representative PB smears from mice in (A).
(G) Representative BM cytospins from mice in (A).
(H) Representative spleen cytospins from mice in
(A). Blood smears and cytospins were stained with
May-Gr€unwald and Giemsa. Analysis is repre-
sentative of three replicates per genotype from a
total of four independent experiments.
(I) Event-free survival comparison of KLG-M (n = 8)
and KLG-E (n = 5) mice performed as in (A). *p <
0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
(F–H) Scale bars, 50 mm. See also Figures S1 and
S2 and Table S1.
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Articleexperimental, CD45.2-derived erythroid lineage cells (EGFP–)
to be distinguished from competitor- and recipient-derived
erythroid cells (EGFP+), and therefore the development of
erythroid lineage phenotypes in Cebpa and Gata2 mutant cells
to be observed. Mice transplanted with FL cells of the four ge-
notypes were monitored by periodic peripheral blood (PB)
analysis (Figures S2B–S2E). This analysis showed comparable
overall reconstitution of PB leukocytes by all four genotypes
(Figure S2F). However, mice transplanted with KLG FL cells
(henceforth KLG mice) showed increased myeloid contribution
after 20 weeks, with no significant differences in lymphoid cell
contribution (Figure S2F). In addition, both KL and KLG mice
showed more rapid reconstitution of erythrocytes, but not of
platelets (Figure S2G).692 Cancer Cell 37, 690–704, May 11, 2020Biallelic Cebpa and Gata2 ZnF1
Mutations Synergistically Induce
Bilineage AEL
Consistent with accelerated myeloid line-
age output from transplanted KLG FL
cells, KLG mice developed leukemia
more rapidly (Figure 1A; average latency
of 8 months) than KL mice (average la-
tency of 10 months) (Table S1). No leuke-
mia was observed in WT or G mice. Mori-
bund mice were characterized by
increased leukocyte count (Figure 1B),
anemia (Figure 1C), thrombocytopenia
(Figure 1D), and splenomegaly (Fig-
ure 1E), consistent with AML. Examina-
tion of blood smears from leukemic
mice showed the presence of leukemic
blasts. However, while KL blasts wereconsistently myeloid (Figure 1F), 5/13 of the examined leukemic
KLGmice contained both myeloid and erythroid blast cells in PB
(KLG-E mice), with the remaining mice showing only myeloid
blast morphology (KLG-M mice). The same pattern was
observed in bone marrow (BM) (Figure 1G) and spleen (Fig-
ure 1H). In addition, KLG-E mice showed prominent dyserythro-
poiesis (Figure 1F), a characteristic feature of AEL (Zuo et al.,
2010). Comparison of survival of KLG-M and KLG-E mice
showed that KLG-E leukemias developed faster than the purely
myeloid KLG-M leukemias (Figure 1I).
Analysis by flow cytometry showed a significant expansion
of mutant CD45.2 immature c-Kit+ Mac-1lo myeloid cells in all
leukemic mice in both BM and spleen (Figures 2A and S3A–




































































































































































































Figure 2. KLG-E Mice Contain Both Myeloblasts and Erythroblasts
in the BM and Spleen
(A) Histogram showing c-KitloMac1+ and c-Kit+Mac1lo cells as a percentage of
7AAD–CD45.1–EGFP– cells in the BM (left panel) and spleen (right panel) in
primary transplanted mice. WT, n = 7 (non-leukemic); G, n = 7 (non-leukemic);
KL, n = 3 (all leukemic); KLG-M, n = 6 (all leukemic); KLG-E, n = 4 (all leukemic)
from a total of three independent experiments.
(B) Histogram showing stage I–IV erythroblast cells as a percentage of
7AAD–CD45.1–EGFP– cells in the BM (left panel) and spleen (right panel) in
primary transplanted mice from (A).
(C) Histogram showing c-KitloMac1+ and c-Kit+Mac1lo cells as a percentage of
7AAD–CD45.1–EGFP– cells in the BM (left panel) and spleen (right panel) of
mice transplanted with KLG-M and KLG-E leukemias, as indicated. Cell
numbers transplanted are shown in Table S2. Five mice were analyzed for
each leukemia phenotype.
(D) Histogram showing stage I–IV erythroblasts cells as a percentage of
7AAD–CD45.1–EGFP–cells in the BM (left panel) and spleen (right panel) of
mice from (C). The results are presented as the mean ± SD.
See also Figures S3 and S4 and Table S2.
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Articleprogenitors (Figures 2B and S3A, S3D, and S3E). Importantly, in
leukemic KLG-E mice, but not KL or KLG-M mice, expansion of
immature CD45.1–EGFP– (i.e., CD45.2 donor-derived)
CD71hiTer119lo erythroblast (corresponding to erythroblast
fraction I; Socolovsky et al., 2001) was observed in BM, and to
an even greater extent in spleen (>20%erythroblasts; Figure 2B).
These CD71hiTer119lo immature erythroblasts were c-Kit+
(Figures S4A–S4D) and accumulated in high numbers in the
spleen (Figures S4C and S4D). Combined with the absence of
EGFP– stage III–IV erythroid progenitors this was consistent
with the morphologically observed accumulation of immature,
leukemic erythroid progenitors in KLG-E BM, spleen, and blood.
Finally, transplantation of KLG-M leukemia cells into irradiated
recipients generated a purely myeloid leukemia (Figures 2C,
2D, and S4E–S4H) within 8 weeks (Table S2) with remaining
CD45.2-derived CD45.1–EGFP– erythroid cells (most likely
derived from residual pre-leukemic HSCs; Bereshchenko et al.,
2009) showing a normal differentiation profile (Figure S4H),
whereas mice transplanted with KLG-E leukemia cells devel-
oped leukemia faster, with an average latency of 5 weeks
(Table S2), and accumulated high levels of both erythroblast
and c-Kit+Mac-1lo myeloid blasts in BM and spleen (Figures
2C, 2D and S4E–S4H), replicating the original disease pheno-
types. Therefore, biallelic Cebpa and Gata2 ZnF1 mutations in
combination, but not separately, are able to induce highly
aggressive, transplantable bilineage AEL.
Identification of the AEL-Sustaining Leukemia-
Initiating Cell
To determine if erythroid and myeloid AEL blasts arose from
the same leukemia-initiating cell (LIC) we examined the CD45.2
stem and progenitor cell compartment in leukemic mice to
identify a putative LIC population(s). We did not observe any
expansion of the BM CD45.2 Lin–Sca-1+c-Kit+ (LSK) stem-
and multi-potent progenitor compartment in leukemic mice
(Figure 3A). In contrast, the BM CD45.2 Lin–c-Kit+ (LK) popula-
tion was significantly expanded in leukemic compared
with non-leukemic mice (Figure 3B). Using our recently
described progenitor phenotyping scheme (Drissen et al.,
2016) (Figures S5A–S5C) we found that CD45.2+ LK cells from
non-leukemic WT and G mice displayed a normal distribution
of myelo-erythroid progenitors (Figure 3C). In contrast, in
leukemic mice the LK compartment consisted principally of
LKCD41–CD150–FcgRII/III+CD55– cells (Figure 3C), the im-
muno-phenotype of NMPs (Figure S5B). We also observed
a significant amount of LKCD41+CD150– cells in leukemic
mice. Normally, these cells are rare and phenotypically hetero-
geneous (Figure S6A). However, in leukemic mice they were
abundant and predominantly FcgRII/III+CD55–, similar to
NMPs, with a small FcgRII/III+CD55+ population observed
selectively in KLG-E leukemias (Figure S6A). We therefore
defined leukemic NMPs (L-NMPs) as LKFcgRII/III+CD55–
(Figure S6B), thereby including both the CD41+ and CD41–
cell populations. From KLG-E mice we also purified LKFcgRII/
III+CD55+ cells (designated L-EoMPs, based on their phenotypic
similarity to the previously defined eosinophil-mast cell progen-
itor) (Drissen et al., 2016) (Figures S5A–S5C) and CD45–Lin–c-
Kit+ cells (designated L-EB, as they have the surface phenotype
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Figure 3. Cebpa and Gata2 Mutant AEL Is Sustained by LICs with an NMP Immuno-Phenotype
(A) Absolute number of LSK in the BM of terminal analyzed primary transplanted mice of the indicated genotypes. The results are presented as the mean ± SD.
Statistical significancewas determined using theMann-Whitney U test. *p < 0.05, **p < 0.01, ***p < 0.001.WT, n = 7; G, n = 9; KL, n = 4; KLG-M, n = 4; KLG-E, n = 3
from a total of five independent experiments.
(B) Absolute number of LK cells in the BM analyzed as in (A). The results are presented as themean ± SD.WT, n = 7; G, n = 9; KL, n = 5; KLG-M, n = 8; KLG-E, n = 5
in five independent experiments.
(C) Myelo-erythroid progenitors as a percentage of donor LK cells in the BM in mice from (B). The results are presented as the mean ± SD.
(D) Terminal analysis of secondary recipients transplanted with purified L-NMPs, L-EoMPs, and L-EB cells. Histogram showing c-KitloMac1+ and c-Kit+Mac1lo
cells as a percentage of 7AAD–CD45.1–EGFP– cells in the BM (left panel) and spleen (right panel). The results are presented as themean ± SD. KLG-M L-NMP, n =
2; KLG-E L-NMP, n = 5; KLG-E L-EoMP, n = 2; KLG-E L-EB, n = 2 in three independent experiments.
(E) Histogram showing stage I–IV erythroblast cells as a percentage of 7AAD–CD45.1–EGFP– cells in the BM (left panel) and spleen (right panel) in mice from (D).
The results are presented as the mean ± SD. *p < 0.05, ***p < 0.005 (combined stage I and II EB; Student’s t test, compared with KLG-M L-NMP). PreNM, pre-
neutrophil-monocyte progenitor; EMkMPP, erythroid-megakaryocyte primed multi-potent progenitor; MegE, megakaryocyte erythroid progenitor; PreCFU-E,
pre-colony forming unit erythroid progenitor; CFU-E, colony forming unit erythroid progenitor
See also Figures S5–S7 and Tables S2 and S3.
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ArticleTransplantation of purified L-NMPs from either KLG-M or KLG-E
mice, or KLG-E L-EoMPs or L-EBs, in all cases re-capitulated the
phenotype of the original disease (Figures 3D, 3E, and S7A–S7H;
Table S2). LIC titration experiments showed comparable
engraftment of KLG L-NMP and L-EoMP, with L-EBs signifi-
cantly lower (Table S3). Given the far greater abundance of L-
NMPs compared with L-EoMPs (Figures 3C and S6B), the
main LIC population in both KLG-M and KLG-E mice was the
L-NMP. Furthermore, KLG-E LICs could re-establish both trans-
formed erythroid and myeloid cells in secondary recipients.
Erythroleukemic L-EBs Show Ectopic Myeloid
Transcriptional Programming
Both normal/pre-leukemic and leukemic progenitors were RNA
sequenced. Clustering using principal components showed
that non-leukemic MBs, EBs, and NMPs clustered according
to cell identity (Figure 4A). The leukemic MB (L-MB) and L-EB
populations clustered closer to the NMP, consistent with a
more immature, progenitor-like state. Using gene set enrichment
analysis (GSEA) (Subramanian et al., 2005) we observed that
erythroid differentiation-specific genes were downregulated in
KLG L-EBs compared with pre-leukemic KLG EBs, whereas694 Cancer Cell 37, 690–704, May 11, 2020myeloid gene expression was upregulated (Figure 4B). In addi-
tion, expression of neutrophil differentiation-specific genes
was lower in KLG-M and KLG-E L-MBs compared with
pre-leukemic KLG MBs (Figure 4C). Therefore, the block in
morphological differentiation along the erythroid and neutrophil
lineages was accompanied by, and likely due to, suppression
of the respective differentiation programs at the molecular level.
Examination of the genes differentially expressed between KLG
L-EB and pre-leukemic EBs (Table S4) identified Cebpa, Cebpb,
Fli1, and Sfpi1 encoding, in addition to C/EBPa, the C/EBPb,
FLI-1, and PU.1 TFs, respectively, as highly upregulated to the
levels observed in normal (WT MB) and transformed myeloid
blasts (KLG-E L-MB, KLG-M L-MB) (Figures 4D and S8A),
whereasGata1,Klf1, and Zfpm1 (encoding FOG-1), all genes en-
coding TFs critical to erythroid development, were strongly
downregulated in L-EBs (Figures 4D and S8A). In contrast,
Gata2 expression was sustained in L-EBs at the same level as
in WT EBs (Figures 4D and S8A). The differentiation block of
L-EBs is therefore accompanied by the expression of several
TFs normally absent in erythroid lineage cells.
To assess if the Cebpa and Gata2 mutant mouse model was














































p value < 0.001
FDR = 0.11
KLG EB > KLG-E L-EB
NES = 1.31
p value < 0.001
FDR = 0.05
NES = -1.42
p value < 0.001
FDR = 0.09
NES = -1.45
p value < 0.001
FDR = 0.10
KLG-E L-EB > KLG EB
KLG-E L-EB > KLG EB
KLG EB > KLG-E L-EB
KLG-M L-MB > KLG MB
KLG-E L-MB > KLG MB
KLG MB > KLG-M L-MB
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Figure 4. Erythroid Leukemia LICs Show Ectopic Myeloid Transcriptional Programming
(A) Principal-component analysis of RNA sequencing data using the top 500 most variable genes across the entire dataset. The ovals have been drawn to
encompass the populations indicated next to them, n = 3 per population.
(B) GSEA of KLG-E L-EB versus KLG EB using preCFU-E (top panel) and preGM gene sets (bottom panel). Normalized enrichment score (NES), p value and false
discovery rate (FDR) are indicated.
(C) GSEA of KLG-ML-MB versus KLGMB (top panel) and KLG-E L-MB versus KLGMB (bottom panel) using a neutrophil differentiation-specific gene set as in (B).
(D) Histograms showing expression levels of selected TF-encoding genesmeasured by RNA sequencing in the indicated cell populations. Values are mean reads
per kilobase million (RPKM) ± SD, n = 3 per population.
(E) tSNE plots of human AEL single cell showing expression of indicated signatures.
See also Figure S8 and Table S4.
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p value < 0.001
FDR = 0.06
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Figure 5. Biallelic Cebpa Mutations Install Ectopic Erythroid Lineage Programming in NMPs
(A) GSEA of KL NMPs versus WT NMPs using pre-granulocyte-macrophage progenitor (preGM) (left panel) and MegE gene sets (right panel). NES, p value and
FDR are indicated. n = 3 per genotype.
(B) GSEA of KLG NMPs versus G NMPs using preGM (left panel) and MegE gene sets (right panel). n = 3 per genotype.
(legend continued on next page)
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Articlehuman AEL patient samples, observing the presence of both
myeloid (CD33+) and erythroid (CD71+CD235a+) blasts, as well
as an expanded CD71–CD235a–CD33+KIT+CD34+ myeloid pro-
genitor population (Figure S8B). Single-cell RNA sequencing
and tSNE-based clustering identified AEL cell populations ex-
pressing human MB, erythroblast, and AML leukemic stem cell
(LSC) gene signatures (Figure 4E), and showed that the LSC-
like population was identified by the same markers as the
expanded CD71–CD235a–CD33+KIT+CD34+ progenitor subset,
whereas cells expressing theMB and erythroblast signatures ex-
pressed CD33, and TFRC and GYPA (which encode CD71 and
CD235a), respectively, consistent with the flow cytometry
data (Figures S8C and S8D; KIT expression not detected in
103 data). Finally, using GSEA a human AEL-specific gene
signature was upregulated in KLG-E compared with KLG-M
L-NMPs (Figure S8E). By both cellular and molecular criteria
the murine AEL model is therefore analogous to human AEL,
and in particular an expanded myeloid progenitor population
with LSC characteristics, analogous to the L-NMP, could be
identified in human AEL samples.
Biallelic Cebpa Mutant NMPs Display Ectopic Erythroid
Lineage Programming
NMPs normally do not have detectable erythroid lineage poten-
tial (Drissen et al., 2016). However, we previously observed that
pre-leukemic HSCs from KL mice were enriched for erythroid
gene expression compared with their WT counterparts (Beresh-
chenko et al., 2009). To determine if a similar effect was present
in Cebpamutant progenitors we compared the gene expression
profiles of pre-leukemic NMPs from the four genotypes (Table
S4). Comparing WT and KL NMPs we observed depletion of
myeloid and enrichment of megakaryocyte-erythroid gene
expression (Figure 5A) in the KLmutant NMPs. The same pattern
was observed comparing G with KLG NMPs (Figure 5B). To
assess the underlying transcriptional reprogramming we
analyzed the expression of key myeloid (Cebpa, Cebpb, Fli1,
and Sfpi1) and erythroid (Gata1, Gata2, Klf1, and Zfpm1) TF-en-
coding genes, along with those encoding more generally ex-
pressed hematopoietic TFs (Ikzf1, Etv6, and Runx1) in the RNA
sequencing dataset. Although the myeloid TFs showed moder-
ate or no regulation (Figure 5C), erythroid TFs were upregulated
in NMPs in the presence of biallelic Cebpa mutation (Figure 5D),
with little change seen for Etv6 or Ikzf1 (Figure 5E). To determine
if the upregulated erythroid TFs were co-expressed with myeloid
TFs at the single-cell level we performed microfluidics-based
qRT-PCR (Figure 5F). This confirmed the observations from
bulk RNA sequencing, and showed that, while WT and G
NMPs expressed multiple myeloid TFs, the expression of multi-
ple erythroid TFs was rare (Figure 5G using genes from Fig-(C) Histogram showing expression levels of selected myeloid TF-encoding genes
mean RPKM ± SD, n = 3 per genotype.
(D) Histogram showing expression levels of selected erythroid TF-encoding gene
(E) Histogram showing expression levels of selected general hematopoietic TF-e
(F) Multiplex qRT-PCR of myeloid and megakaryocytic/erythroid (Mk/E) TF gene
heatmap shows 2–DCt values normalized to Hprt and centered on the mean value
(G) Scatterplot depicting the number of myeloid andMk/E TF genes from (F) co-ex
The average number of myeloid (M) and Mk/E genes expressed is shown, as are
See also Table S4.ure 5F). In contrast, in the presence of biallelic Cebpa mutation
NMPs consistently co-expressed myeloid and erythroid TFs
(Figure 5G). This analysis showed that, in the presence of the
KL genotype the frequency of erythroid TF expression was
increased, whereas myeloid TFs, while still expressed, were
present at lower frequencies. The expression of Ikzf1 and
Etv6 was not affected by Cebpamutation (Figure 5F), consistent
with the RNA sequencing data.
Gata2 ZnF1 Mutation Promotes Erythroid and Restricts
Myeloid TF Chromatin Access
Although biallelic Cebpa mutation upregulated erythroid TFs,
we only observed AEL in KLGmice, indicating an additional layer
of regulation imposed by Gata2 ZnF1 mutation. Exome
sequencing of KLG-E and KLG-M tumors did not identify any
distinct, recurring coding sequence mutations (Table S5),
arguing against additional genetic drivers being involved. We
therefore performed ATAC sequencing of purified KL, KLG-M,
and KLG-E L-NMPs to assess whether these were epigenetically
distinct. Clustering based on peak intensity or TF motif chro-
matin accessibility (Figure 6A; Table S6) clearly separated KL
and KLG-M from KLG-E L-NMPs. Motif-based clustering also
separated pre-leukemic KL and KLG NMPs (Figure 6B; Table
S6), and we observed a clear correlation of motif-enrichment in
leukemic and pre-leukemic samples: in both KLG-E L-NMPs
and KLG NMPs chromatin access to erythroid TF motifs
(GATA, NF-E2, and RREB) was increased, whereas access to
myeloid TF motifs (C/EBP, PU.1, and SPI-B) was decreased
(Figure 6C). Access to individual promoters was similarly corre-
lated (Figure 6D). However, the expression level of the cognate
TF-encoding genes was not different between KL and KLG
NMPs (Figures 5C, 5D, and 6E). The Gata2 G320D mutation
therefore generates an erythroid-permissive chromatin state in
pre-leukemic NMPs, without altering the expression of erythroid
or myeloid TFs, a chromatin state that is preserved upon their
transformation to KLG-E L-NMPs.
To assess the effect of the transcriptional and epigenetic
changes induced by Cebpa and Gata2 mutation on lineage
commitment we analyzed pre-leukemic BM progenitors 6 weeks
post-transplantation (Figure S5C), before any increase in
myeloid cell output in KLG mice. Both the LSK and LK popula-
tions were increased by Cebpa mutation (Figures 7A and 7B),
and the most significant expansion was of Gata1-expressing
myelo-erythroid progenitors, and in particular those with
erythroid and megakaryocytic lineage potential; EMkMPPs,
MegEs, MkPs, PreCFU-Es and CFU-Es (Figures 7C–7E),
providing a cellular mechanism for the more rapid reconstitution
of erythrocytes by KL and KLG FL cells after transplantation (Fig-
ure S2G). By normalizing the size of the progenitor populations tomeasured by RNA sequencing in NMPs of the indicated genotypes. Values are
s, as in (C).
ncoding genes, as in (C).
s on single NMPs. WT, n = 192; G, n = 192; KL, n = 384; KLG, n = 384. The
for each gene.
pressed in single WT, G, KL, and KLG NMPs. Each dot represents a single cell.
the p values (Wilcox test) against the WT distribution for each gene set.





B Figure 6. Mutation of GATA-2 ZnF1 Induces
an Erythroid-Permissive Chromatin State
(A) Leukemic KL, KLG-M, and KLG-E L-NMP were
hierarchically clustered using Pearson correlation
of ATAC sequencing peak intensities (left panel)
and motif accessibility (right panel). n = 3 per ge-
notype.
(B) Pre-leukemic KL (n =3) and KLG NMP (n = 2)
samples were hierarchically clustered using Pear-
son correlation of motif accessibility.
(C) Plot showing linear modeling of the correlation
between TF motifs with significantly different
accessibility in AEL versus AML L-NMPs, samples
from (A, x axis) and KL versus KLG NMPs, samples
from (B, y axis). The linear model and associated
R2 and p values are shown.
(D) Plot showing linear modeling of the correlation
between promoters with significantly different
accessibility as in (C).
(E) Expression of genes encoding cognate TFs for
correlated motifs from (C) measured as in Figures
5C–5E. TFs already included in Figures 5C–5E are
not shown. Values are mean RPKM ± SD, n = 3 per
genotype.
See also Tables S5 and S6.
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Articlethat of WT mice we observed that EMkMPPs and CFU-Es were
selectively expanded in KLG compared with KLmice (Figure 7F),
demonstrating a co-operative effect of the two mutations on the
progenitor hierarchy, and in particular in the generation of
committed erythroid CFU-E progenitors.
Pre-leukemic NMPs and Erythroleukemic KLG L-NMPs
Are Bipotent at the Single-Cell Level
These data were compatible with Cebpa and Gata2 mutation
co-operating to install erythroid lineage potential in NMPs. We
therefore cultured single WT and KLG NMPs under conditions
compatible with both myeloid and erythroid lineage develop-
ment, and assessed their differentiation by both morphology
and gene expression. As expected, WT NMPs generated cells
with neutrophil and monocyte morphology (Figures 8A and
8B) and predominantly myeloid gene expression (ratio of
erythroid [Gata1, Gata2, Zfpm1, Gfi1b, Gypa, and Klf1] to
neutrophil [Cebpa, Cebpe, Ctsg, Elane, Mpo, Prtn3, Sfpi1,
and Gfi1] gene expression frequency: 0.41) (Figures 8C and
8D). In contrast, KLG NMPs generated colonies containing
immature myeloid and erythroid cells (Figures 8A and 8B),
with the immature myeloid morphology in KLG colonies
likely due to the increased proliferative capacity of myeloid
progenitors after loss of C/EBPa-mediated E2F repression698 Cancer Cell 37, 690–704, May 11, 2020(Porse et al., 2005). KLG colonies ex-
pressed erythroid genes at significantly
higher frequency compared with WT
NMP colonies (ratio of erythroid to
myeloid gene expression frequency:
0.97; p value versus WT = 8.6 3 109),
and consistently co-expressed erythroid
and neutrophil lineage-specific genes
demonstrating the generation of both
neutrophil and erythroid lineage cellsfrom a single KLG NMP (Figures 8C and 8D). KLG NMPs
therefore represent a neomorphic progenitor population
capable of efficiently generating both neutrophil and erythroid
lineage cells, replicating the lineage pattern observed in KLG
erythroleukemic mice.
The observation that pre-leukemic KLG NMPs were bipotent
neutrophil-erythroid progenitors, raised the possibility that
L-NMPs were also bipotent, and generated both myeloid and
erythroid blasts at the single-cell level. To test this hypothesis
we isolated KLG L-NMPs from KLG-E mice, transduced them
with a lentiviral barcode library containing 725 barcodes, con-
tained in an EGFP-expressing viral backbone (Figure 8E) (Bel-
derbos et al., 2017), and transplanted the transduced cell pop-
ulation into irradiated recipients. After 4 weeks we re-isolated
EGFP-expressing L-NMPs, L-EBs, and L-MBs (Figures 8F–
8H), retrieved the barcodes from their genomic DNA, and iden-
tified them by next-generation sequencing. By comparing the
barcodes retrieved from L-EBs and L-MBs we found that there
was a highly significant overlap in three independent
transplantations (Figure 8I), demonstrating that the trans-
planted L-NMPs remain bipotent after transformation. Impor-
tantly, the number of barcodes retrieved from all three
populations was significantly higher than randomly expected
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Figure 7. Mutation of GATA-2 ZnF1 Impairs Differentiation at Distinct Stages on Myelo-Erythroid Differentiation
(A) Representative FACS plots LSK and LK cells in the BM in pre-leukemic mice 6 weeks post-transplantation.
(B) Absolute number of LSK (left panel) and LK cells (right panel) in the BM in mice from (A).
(C) Absolute number of phenotypic EMkMPP (left panel) and EoMP progenitors (right panel) in the BM in mice from (A).
(D) Absolute number of phenotypic committed erythroid/megakaryocytic progenitors in the BM in mice from (A).
(E) Absolute number of phenotypic committed neutrophil-monocyte progenitors in the BM in mice from (A).
(legend continued on next page)
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C Figure 8. AEL LICs Are Bipotent at the Sin-
gle-Cell Level
(A) Cytospins of single NMP colonies stained with
May-Gr€unwald and Giemsa. Scale bars, 50 mm.
(B) The morphology of colonies generated from
single WT and KLG NMPs is shown. Gran, gran-
ulocytic; Mono, monocytic; Ery, erythroid; ImMy,
immature myeloid. The total number of colonies
scored for each genotype is indicated.
(C) Multiplex qRT-PCR of myeloid and erythroid
genes on colonies derived from single NMPs. WT,
n = 45; KLG, n = 85. The heatmap shows 2–DCt
values normalized to the average of Gapdh and
Hprt and centered on the mean value for each
gene.
(D) Scatterplot depicting the number of myeloid
and erythroid genes co-expressed in individual
WT and KLG colonies from (C).
(E) Schematic of the lentiviral barcoded library
vector.
(F) Sorting strategy for re-isolation EGFP+ L-EBs
from mice transplanted with barcoded KLG-E L-
NMPs. Data representative of three independent
transplantation experiments are shown. Percent-
ages of re-isolated transduced cells are indicated.
(G) Sorting strategy for re-isolation of EGFP+ L-
MBs as in (F).
(H) Sorting strategy for re-isolation of EGFP+ L-
NMPs as in (F).
(I) Venn diagram depicting the overlap of barcodes
retrieved from the populations isolated above (F–
H). Data are representative of three independent
transplantation experiments. Mean p value ± SD of
three independent transplantations is shown (hy-
pergeometric test).
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Articlebarcoded L-NMPs self-renewing and at the same time gener-
ating both L-MB and L-EB blasts. Together, these results there-
fore show that KLG NMPs retain their neomorphic neutrophil-
erythroid lineage potential after leukemic transformation, allow-
ing individual L-NMPs to propagate the disease and to
generate both transformed myeloid and transformed erythroid
blasts.
DISCUSSION
We here show that biallelic Cebpa and Gata2 ZnF1 mutations
cooperate during myeloid leukemogenesis, and in particular(F) Number of myelo-erythroid progenitors from (C and D) and stage I–IV erythroblasts normalized to WT v
analysis was performed on five to six replicates from two independent experiments. Stage I–IV erythroblast
from one experiment. The results were analyzed using a multiple comparison ANOVA. The results are presen
0.001, ****p < 0.0001.
700 Cancer Cell 37, 690–704, May 11, 2020that these mutations are sufficient to
induce bilineage AEL. Our murine AEL
model resembles human AEL, contain-
ing both myeloid and erythroid blasts,
the cardinal feature of bilineage AEL.
In addition, the major LIC population in
the murine AEL model has an NMP im-
mune-phenotype, and we identify a cor-
responding expanded CD33+CD34+-KIT+ myeloid progenitor in human AEL, which expressed a
human AML LSC signature.
The L-NMPs capable of initiating bilineage AEL are bipotent at
the single-cell level. This L-NMP is similar to that sustaining
Cebpa mutant neutrophil lineage leukemia (Bereshchenko
et al., 2009; Kirstetter et al., 2008); however, while, NMPs nor-
mally generate only neutrophils and monocytes (Drissen et al.,
2016), in the presence of both biallelic Cebpa and Gata2 ZnF1
mutations they display ectopic erythroid differentiation poten-
tial, as well as the capacity to generate bilineage L-NMPs.
Here, we find that Cebpa and Gata2 mutations make distinct
contributions to erythroid lineage programming of NMPs:alues in mice from (A). Myelo-erythroid progenitor
analysis was performed on three to four replicates
ted as the mean ± SD. *p < 0.05, **p < 0.01, ***p <
ll
Articlebiallelic Cebpa mutation increases the expression of erythroid
lineage TFs, while Gata2 ZnF1 mutation increases erythroid TF
and decreases myeloid TF chromatin access. This erythroid-
permissive chromatin state is sustained in bilineage KLG-E L-
NMPs, but not myeloid-only KLG-M L-NMPs, further supporting
its role in maintaining the bilineage AEL phenotype.
Genetic alterations affecting chromatin regulators are present
in themajority of AML tumors, withDNMT3A and TET2mutations
the most common (Metzeler et al., 2016). In genetic modeling
such mutations have been shown to de-regulate methylation of
both tumor suppressor (Rasmussen et al., 2015) and differentia-
tion-specific enhancers (Yang et al., 2016), and in the case of
DNMT3A to control the lineage identity of the resulting leukemia
(Yang et al., 2016). We here identify GATA-2 as a ‘‘non-canoni-
cal’’ chromatin regulator that is able to selectively control access
to lineage-specific TFs motifs, thereby controlling the phenotype
of the resulting leukemia. This is consistent with GATA-2 physi-
cally and functionally interacting with both myeloid (PU.1 and
C/EBP) and erythroid TFs (KLF1, FOG-1, and SCL/LMO2/
LDB1) (Collin et al., 2015), and altered crosstalk within this TF
network upon Gata2 ZnF1 mutation contributing to chromatin
reorganization.
The mechanisms underlying erythroid lineage transformation
in AEL remain unknown. We here find that transformed L-EBs
upregulate a number of genes encoding myeloid lineage TFs,
including Fli1 and Sfpi1. Overexpression of both these genes
through retroviral insertion induces pure erythroid leukemia
(Ben-David et al., 1990; Moreau-Gachelin et al., 1988), and their
continued expression is necessary and sufficient to block
erythroid differentiation of transformed erythroblasts (Rao
et al., 1997; Starck et al., 1999). Importantly, FLI-1 and PU.1
cross-antagonize the key erythroid TFs GATA-1, GATA-2, and
KLF-1: PU.1 is able to suppress GATA-1 both transcriptionally
(Nerlov and Graf, 1998) and through protein-protein interaction
(Rekhtman et al., 1999), and FLI-1 inhibits KLF1-mediated tran-
scription (Starck et al., 2003). Therefore, the sustained expres-
sion of FLI-1 and PU.1 in L-EBs can explain the absence of
both KLF-1 and GATA-1 expression, and the observed differen-
tiation block. Importantly, PU.1–GATA inhibition is reciprocal, as
GATA-1 and GATA-2 also block PU.1 function (Nerlov et al.,
2000; Zhang et al., 2000). Therefore, sustained expression of
GATA-2 in L-EBs, in conjunction with decreased chromatin ac-
cess of myeloid TFs, may prevent their conversion to myeloid
lineage cells, despite the extensive myeloid transcriptional re-
programming of L-EBs.
In summary, we here identify combined Cebpa and Gata2
mutations as causative of bilineage AEL, providing a validated
pre-clinical model for this leukemia subtype. In addition, we
identify a previously uncharacterized role of Gata2 ZnF1 in con-
trolling lineage fate throughmodification of TF chromatin access.
The loss of myeloid and gain of erythroid TF chromatin access in
the presence of Gata2 ZnF1 mutation may be relevant to the
myeloid differentiation block characteristic of AML, and in partic-
ular act cooperatively with altered TF gene expression induced
by biallelic Cebpa mutation, providing a molecular basis for the
correlation of CEBPA and GATA2 mutation in AML. These
studies underscore the usefulness of accurate genetic modeling
and the study of the pre-leukemic state in understanding the eti-
ology of AML.STAR+METHODS
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See Table S8
Bacterial and Virus Strains
pEGZ2-linkerBC322 barcoding library (Belderbos et al., 2017)
Biological Samples
AEL patient samples (OX1164; AYL050; MKH048;
STB115)
MDSBio NA
Normal adult human bone marrow AllCells NA
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Critical Commercial Assays
CellDirect One-Step qPT-PCR kit ThermoFisher Cat#11753100
Biomark 192.24 Gene Expression IFCs Fluidigm Cat#101-0351
Nextera XT Index Kit Illumina Cat#FC-131-1001
PEIpro Polyplus transfection Cat#115-100
Deposited Data
Raw and analyzed data This paper GEO: GSE141813
Human M6 AEL gene expression data (Taskesen et al., 2015)
(Taskesen et al., 2011)
(Wouters et al., 2009)
GEO: GSE14468
Experimental Models: Cell Lines
HEK293T/17 cells ATCC Cat#ATCC CRL-11268
Experimental Models: Organisms/Strains
Mouse: CD45.1/CD45.1-Gata1-EGFP (Drissen et al., 2016) NA
Mouse: CebpaK/L;Gata2D/+ This paper, (Bereshchenko
et al., 2009)





Flowjo FlowJo LLC RRID:SCR_008520
FastQC Babraham Bioinformatics http://www.bioinformatics.babraham.ac.uk/
projects/fastqc; RRID:SCR_014583
STAR (Dobin et al., 2013) https://github.com/alexdobin/STAR/releases;
RRID:SCR_015899
featureCounts (Liao et al., 2013) http://subread.sourceforge.net/;
RRID:SCR_012919
DESeq2 (Love et al., 2014) https://bioconductor.org/packages/release/
bioc/html/DESeq2.html;
RRID:SCR_015687
GSEA (Subramanian et al., 2005) http://software.broadinstitute.org/gsea/index.jsp;
RRID:SCR_003199
Cell Ranger 10x Genomics https://support.10xgenomics.com/single-cell-
gene-expression/software/overview/welcome;
RRID:SCR_017344
Seurat (Butler et al., 2018) https://satijalab.org/seurat/; RRID:SCR_016341
Trim Galore Babraham Bioinformatics https://github.com/FelixKrueger/TrimGalore;
RRID:SCR_016946
Bowtie2 (Langmead and Salzberg, 2012) http://bowtie-bio.sourceforge.net/bowtie2/
index.shtml; RRID_005476
Samtools (Li et al., 2009) http://www.htslib.org/; RRID:SCR_002105
Picard Broad Institute https://broadinstitute.github.io/picard/;
RRID:SCR_006525
MACS2 (Zhang et al., 2008) https://github.com/taoliu/MACS;
RRID:SCR_013291
Homer (Heinz et al., 2010) http://homer.ucsd.edu/homer/;
RRID: SCR_010881
ChromVAR (Schep et al., 2017) https://github.com/GreenleafLab/chromVAR
BWA algorithm Broad Institute https://arxiv.org/abs/1303.3997
GATK (McKenna et al., 2010) https://gatk.broadinstitute.org/;
RRID: SCR_001876
Strelka2 (Kim et al., 2018) https://github.com/Illumina/strelka
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Manta (Chen et al., 2016) https://github.com/Illumina/manta
VarDict (Lai et al., 2016) https://github.com/AstraZeneca-NGS/VarDict
Ensembl VEP (McLaren et al., 2016) https://useast.ensembl.org/info/docs/tools/
vep/index.html; RRID: SCR_007931
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ArticleLEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Claus
Nerlov (claus.nerlov@imm.ox.ac.uk). The generation of theGata2G320Dmouse strain is described below and themouse line is avail-
able upon request.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals
All mouse lines were maintained on a pure C57Bl/6J genetic background. All mice were bred and maintained in accordance with
UK Home Office regulations. Experiments were conducted following ethical approval by the University of Oxford Medical Sciences
Division Animal Welfare and Ethical Review Body under a project license form the UK Home Office (license number 30/3359).
Knock-in mice expressing the Gata2 G320D (Gata2D/+) allele were generated by Cyagen Biosciences Inc, California, USA on a
C57Bl6/J background. TheG320Dmutationwas introduced into exon four by site-directedmutagenesis. The target vector contained
a Neomycin resistance (Neo) cassette flanked by Frt sites and a thymidine kinase cassette used for negative selection of directly in-
tegrated vectors (Figure S1A). After homologous recombination in ES cells and germ line transmission of the correctly targeted allele,
the Neo cassette was removed by Flp-mediated recombination.
Gata2D/+ mice were combined with knock-in mice containing a C-terminal Cebpa mutation (lysine insertion after C/EBPa amino
acid 313; K313KK mice or K allele (Bereshchenko et al., 2009)). Gata2D/+;CebpaK/+ mice were then time-mated to knock-in mice
carrying a STOP codon in the p42-specific N-terminal part of C/EBPa (L-allele; (Kirstetter et al., 2008)) to produce single (Gata2D/+),
double (CebpaK/L) and triple transgenic mutant FL cells (CebpaK/L;Gata2D/+), as well as WT control FL cells.Gata2D/+ mice were bred
to homozygosity and primary Gata2D/+ and Gata2D/D mice were analyzed between 4-5 weeks of age. Genotyping was performed
using primers in Table S7.
Human BM Samples
AEL samples were obtained from MDSBio and were consented for research purposes. Sample OX1164 was a 48 year old female
with add(3q), add(5q) cytogenetics. Sample AYL050 was a 47 year old female and was negative for NPM1, FLT3 ITD and FLT3
D835 mutations. Sample MKH048 was a 69 year old male and sample STB115 was a 73 year old male. There is no mutational or
cytogenetic data for samples MKH048 and STB115. All samples were analyzed using flow cytometry. Samples OX1164 and
AYL050were subjected to single cell RNA sequencing. Normal adult humanBMwas obtained fromAllCells (AllCells, California, USA).
Cell Lines
HEK293T/17 cells (ATCC, Virginia, USA) used for barcoding library virus product were cultured in DMEM (Thermo Fisher
Scientific, Massachusetts, USA) with 10% FSC (Thermo Fisher Scientific), NEAA (Thermo Fisher Scientific) and 2 mM L-glutamine
(Thermo Fisher Scientific) and incubated in 37C, in 5% CO2, with R95% humidity. Virus was prepared when the cells were within
six passages after they were obtained from ATCC, without further cell line authentication.
METHOD DETAILS
Competitive Transplantation
CD45.1/CD45.2-Gata1-EGFP adult mice (8-13 weeks old) were utilized as recipients (Drissen et al., 2016). Competitive transplanta-
tions were performed by using 2.5*105 CD45.2 FL cells and 2.5*105 CD45.1/CD45.2-Gata1-EGFP BM competitor cells into
lethally irradiated recipients (two times 500 rads). For pre-leukemia analysis mice were culled at 6 weeks post-transplantation.
For leukemia analysis mice were monitored up to 52 weeks post-transplantation. Mice were culled earlier if mice became hunched
with pale paws, if PB WBC count was R15*109/L, or if RBC count was %7*1012/L.
For secondary transplants lethally irradiated CD45.1/CD45.2-Gata1-EGFP adult mice (8-13 weeks old) were utilized as recipients.
Bulk secondary transplants were performed by transplanting 5-7.5*105 BM cells with 2.5*105 CD45.1/CD45.2-Gata1-EGFP BM
cells for radioprotection into CD45.1/CD45.2-Gata1-EGFP lethally irradiated recipients. For secondary transplants using sorted
cell populations, all cells that were collected from the sort were split into two recipients with 2.5*105 CD45.1/CD45.2-Gata1-EGFP
BM cells for radioprotection into CD45.1/CD45.2-Gata1-EGFP lethally irradiated recipients. Secondary transplants were alsoe4 Cancer Cell 37, 690–704.e1–e8, May 11, 2020
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CD45.1/2 BM cells for radioprotection into CD45.1 or CD45.1/2 lethally irradiated recipients.
For comparing WT, Gata2D/+ and Gata2D/D BM cell (CD45.2 allotype) competitive reconstitution adult mice (7-12 weeks old;
CD45.1/2 allotype) were utilized as recipients. Competitive transplantations were performed using 5*105 CD45.2 BM donor cells
and 5*105 CD45.1 WT BM competitor cells into lethally irradiated recipients (two times 500 rads). Bulk secondary transplants
were performed by transplanting 10*106 BM cells, from primary transplanted mice 17-18 weeks post-transplantation, into lethally
irradiated CD45.1/2 recipients.
Flow Cytometry
Details of murine antibodies and viability dyes used for each staining panel are shown in Table S8. All antibodies were used at pre-
determined optimal concentrations. Hematopoietic stem and progenitor cells, myelo-erythroid progenitors, leukemic myeloid cells,
erythroblast stages, platelets and erythrocytes were analyzed as previously described (Bereshchenko et al., 2009; Carrelha et al.,
2018; Drissen et al., 2016, 2019; Pronk et al., 2007; Socolovsky et al., 2001). In staining where anti-FcgRII/III antibody was not
included, cells were pre-incubated with Fc-block. Gates were set using a combination of fluorescence minus one controls and
populations known to be negative for the antigen. Cell acquisition and analysis were performed on a BD LSRFortessa (BD Biosci-
ences, California, USA) using BD FACSDivaTM software (BD Biosciences). Cell sorting was performed on a BD FACSAriaII cell sorter
(BD Biosciences). Analysis was performed using Flowjo software version 10.0.8 (Flowjo LLC, Oregon, USA).
RNA Sequencing Library Preparation
100 MB (defined as 7AAD–cKitloMac-1+CD45.2+), EB (defined as 7AAD–CD45.1–EGFP–CD71hiTer119loc-Kit+) and NMP (defined
as LKFcgRII/III+CD45.2+) per biological replicate, from pre-leukemic and leukemic stages, were sorted into 4 ml of lysis buffer con-
taining; 0.2% Triton X-100 (Sigma-Aldrich, Missouri, USA), 2.5 mMOligodT (Biomers, Ulm, Germany), 2.5 mM dNTPs (Thermo Fisher
Scientific), RNase Inhibitor 20 U (Takara Bio USA, Inc, California, USA) and ERCC spike-in 1:4*106 (Thermo Fisher Scientific). cDNA
synthesis and PCR amplification were performed based on the published Smart-seq2 protocol (Picelli et al., 2014) with some mod-
ifications. SMARTScribe RT enzyme (Takara Bio USA, Inc) was used in the RTmix (50U) and SeqAMP enzyme (Takara Bio USA, 50U)
was used for the PCR step for 18 cycles. cDNA traces were bead-purified using Ampure XP beads (Beckman Coulter, California,
USA). cDNA was evaluated using a high sensitivity NGS fragment analysis kit (Advanced Analytical, Milton Keynes, UK) on a Frag-
ment Analyzer. cDNA was quantified using PicoGreen (Thermo Fisher Scientific). Normalized cDNA traces were used for library
preparation using aminiaturized version of the Nextera XT Kit (Illumina, California, USA). After tagmentation and 12 cycles of barcod-
ing PCR, tagmented libraries were purified using AmpureXP beads, evaluated using a high sensitivity DNA kit on an Agilent 2100 Bio-
analyzer (Agilent, California, USA) and quantified using a Qubit (Invitrogen, California, USA). Finally, libraries were pooled and
sequenced on four lanes on a NextSeq 500 (Illumina), using 75 bp single-end reads.
Cell Culture
100 CebpaK/L;Gata2D/+ or 300 WT CD45.2 LKFcgRII/III+ BM cells were sorted from mice transplanted with 2.5*105 CD45.2 FL cells
and 2.5*105 CD45.1/CD45.2 BM competitor cells 6 weeks post-transplantation. Cells were seeded into 1 ml of methylcellulose me-
dium (Methocult, M3434, STEMCELL Technologies) and incubated in 37C, in 5% CO2, with R95% humidity. After 8 days colonies
(R30 cells) were counted and colonies were picked by taking 1 ml of cells from the colony and re-suspending in awell of a 96well plate
containing 200 ml PBS + 5% FCS. Cell suspension was then split into two separate plates. Both plates were spun down at 500 g for
5mins at 4C. Supernatant was then removed. One plate was re-suspended in 15 ml of lysis buffer containing 14.85 ml of CellDirect 2x
reactionmix (Thermo Fisher Scientific) and 0.15 ml of SUPERase-In RNase Inhibitor (Thermo Fisher Scientific), then flash frozen on dry
ice and stored at –80C formultiplex qRT-PCR analysis. The second plate was re-suspended in 20 ml of PBS + 20%FCS to be used to
make a cytospin.
Multiplex qRT-PCR Analysis
Multiplex quantitative real-time PCR was performed on single cells, 50 cells, or picked colonies from methylcellulose cultures.
CellDirect One-Step qPT-PCR kit (Thermo Fisher Scientific) was used according to manufacturer’s protocol for preparation and
amplification of cDNA. The BioMark 192.24 Dynamic Array platform (Fluidigm, California, USA) and Taqman assays (Thermo Fisher
Scientific) were used to perform the multiplex qRT-PCR according to the manufacturer’s instructions (Table S7).
Morphology and Cell Counts
Blood smears were made using 3.5 ml of blood. 10*104 BM or spleen cells were used to make cytospins. Air-dried cytopsins
and blood smears slides were stained with May-Gr€unwald (Sigma-Aldrich) and Giemsa (Sigma-Aldrich) reagents. WBC, RBC and
platelet parameters from the PB were measured using a Sysmex KX-21N (Sysmex, Milton Keynes, UK).
In Vivo Barcoding
5*105 CebpaK/L;Gata2D/+ leukemic BM cells were co-transplanted with 2.5*105 CD45.1 BM cells into lethally irradiated CD45.1
recipients. Four weeks post-transplantation mice were culled and 1*105 CD45.2+LKFcgRII/III+CD55– BM cells were sorted and
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USA), 10 ng/ml hIL-6 (Peprotech), and 10 ng/ml mIL-3 (Peprotech). To generate the pEGZ2 lentiviral barcoding library (Belderbos
et al., 2017) (total 725 different barcodes) HEK293T cells (ATCC, Virginia, USA) were transfected with the pGIPZ-based library,
pMD2.G and psPAX2 plasmids using PEI Pro (Polyplus Transfection, New York, USA). Harvests were collected 48 and 72 h post
transfection, combined and concentrated by ultracentrifugation (2 h at 98,000 g, 4C). Cells were transduced with barcoding library
at an MOI of 10, defined as the titre on HEK293T cells divided by the number of L-NMPs. This generated an L-NMP infection rate of
ca. 15%. Cells were incubated at 37C, 5% CO2, for 8 h. Cells were then co-transplanted with 2.5*10
5 WT CD45.1 BM cells into
CD45.1 lethally irradiated recipients. Three weeks post-transplantation mice were culled. Transduced leukemic NMPs (CD45.2+-
GFP+LKFcgRII/III+CD55–) from the BM, transduced leukemic erythroblasts (CD45.1–GFP+CD71hiTer119lo) and transduced leukemic
myeloblasts (CD45.2+GFP+c-KitloMac1+) were sorted from BM and spleen. Leukemic erythroblasts and myeloblasts were pooled
separately, and DNA was extracted from cell pellets using a QIAamp DNA micro kit (Qiagen, Maryland, USA). DNA was quantified
using a Qubit (Invitrogen). Barcode sequences were amplified with primers designed around the barcoding region with Nextera
XT compatible overhangs allowing for indexing and a stagger sequence in the forward primers between Nextera XT compatible over-
hangs and forward sequence to defer cluster calling when sequencing (Krueger et al., 2011) (Table S7). PCR products were bead-
purified using Ampure XP beads. PCR products were then evaluated using a high sensitivity DNA kit on an Agilent 2100 Bioanalyzer,
and quantified using a Qubit. 15 ng of PCR products were used for library preparation using a Nextera XT kit. Libraries were purified
using AmpureXP beads, evaluated using a high sensitivity DNA kit on an Agilent 2100 Bioanalyzer, and quantified using a Qubit.
Finally, libraries were pooled and sequenced on a MiSeq (Illumina), using 150 bp paired-end reads.
Single Cell 10x Chromium Library Preparation
8700 Lin–CD71+CD235a+ and 8700 Lin–CD71–CD235a– single cells were sorted from two human AEL samples. Libraries were pre-
paring using the chromium single cell 3’ reagent kits v2 (10x Genomics, California USA) according to manufacturer’s protocol.
ATAC Sequencing Library Preparation
500 L-NMPs were sorted into lysis buffer containing TD tagmentation buffer (Illumina), 1% digitonin (Promega, Wisconsin USA), 10%
Tween 20 (Sigma-Aldrich) and PBS (Thermo Fisher Scientific). After cells were sorted into the lysis buffer the Tn5 transposase was
then added and immediately incubated at 37C for 30 mins with an agitation at 300 rpm. Samples were then purified using a Qiagen
MinElute Kit (Qiagen). Samples were then PCR amplified and indexed using NEBNext High-Fidelity 2x PCR master mix (NEB, Mas-
sachusetts USA) and P7 and P5 primers containing Nextera adaptor sequences (Table S7). PCR products were then purified using
Ampure XP beads and evaluated using a High Sensitivity D1000 Screen Tape (Agilent) on a TapeStation (Agilent). Samples were
quantified using an NEBNext Library Quant Kit for Illumina (NEB). Finally, libraries were pooled and sequenced on a NextSeq (Illu-
mina), using 40 bp paired-end reads; 40 cycles R1 and 40 cycles R2.
Whole Exome Sequencing Library Preparation
DNA was extracted from frozen cell pellets using a QIAamp DNA minikit (Qiagen) and DNA quantified using a Qubit. Exomes were
captured using a Aglient SureSelect Mouse All Exon Kit (Agilent, California, USA), libraries were sequenced on a HiSeq (Illumina),
using 150 bp paired-end reads.
QUANTIFICATION AND STATISTICAL ANALYSIS
Flow Cytometry
For significance testing of blood analysis the D’Agostino & Pearson normality test was first used to determine if data fell into a normal
distribution. If data did not have a normal distribution then amultiple comparison Kruskal-Wallis test was performed. If the data had a
normal distribution then a multiple comparison ANOVA was performed.
RNA Sequencing Analysis
Following quality control analysis with the fastQC package (http://www.bioinformatics.babraham.ac.uk/projects/fastqc), reads were
aligned using STAR (Dobin et al., 2013) against the mm10 mouse reference genome. Gene expression levels were quantified as
read counts using the featureCounts function from the Subread package (Liao et al., 2013) with default parameters. The read counts
were used for the identification of global differential gene expression between specified populations and/or genotypes using the
DESeq2 package (Love et al., 2014). Reads per kilobase of transcript per million (RPKM) values were then calculated. Genes
were considered differentially expressed between populations and/or genotypes if they had an adjusted p value of less than 0.05.
The pheatmap function was used to generate a heatmap, and prcomp function was used to generate a principal component analysis,
in R statistical programming environment (www.r-project.org). Gene-set enrichment analysis (GSEA) was performed using GSEA
software (Mootha et al., 2003; Subramanian et al., 2005) using previously described preGM, MegE, preCFU-E (Bereshchenko
et al., 2009; Mancini et al., 2012) and neutrophil gene sets (de Graaf et al., 2016).e6 Cancer Cell 37, 690–704.e1–e8, May 11, 2020
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Ct values were generated using the BioMark Real-Time PCR analysis software (Fluidigm). Each amplification curve for each gene and
each cell was visually inspected on the BioMark Real-Time PCR analysis software. Any outliers that were not automatically detected
from the software were manually changed to fail. Data analysis was then performed in R statistical programming environment. Ct
values of all assays marked as ‘Fail’ were set as undetected (Ct = 999). A histogram was generated using Excel (Microsoft, Wash-
ington, USA) to analyze the Ct values for the housekeeping genes. Cut-offs’ for the housekeeping genes Ct values were set in accor-
dance to the histogram analysis. Cells that had a housekeeping gene Ct value that did not meet the cut-off, or were undetected, were
removed from analysis. Ct values were then normalized to the housekeeping gene. If more than one housekeeping gene was used in
the assay then a mean was calculated for the housekeeping genes. Ct values were normalized to the mean of the housekeeping
genes. 2–(Normalized Ct) was then used for analysis. 2–(Normalized Ct) values for each gene were visually inspected and outliers removed.
Differential gene expression statistical significance between genotypes was performed using the Wilcoxon signed-rank test. Differ-
ential gene expression frequency statistical significance between genotypes was performed using a Fisher’s exact test. P value
from the two tests were combined using Fisher’s method. Pheatmap function was used to generate a heatmap. The sum of myeloid
and E/Mk genes detected in each cell was used to generate scatterplots using ggplot2 function in R statistical programming
environment.
Barcode Analysis
Raw fastq sequencing data files were demultiplexed using Illumina indices and analyzed using a custom-written script in R
statistical programming environment. All reads were searched for sequencing matching the following barcode region:
GGNNNACNNNGTNNNTANNNCANNNTGNNN. Barcodes with exact matches with a minimum representation of one read in the
sample with lowest sequencing depth were included in subsequent analysis. Venn-diagramswere generated using the VennDiagram
Rpackage. P valueswere calculated using the hypergeometric test for 2-way overlap (probability of achieving the obtained overlap of
L-EB and L-MB barcodes by chance from a pool of 725 barcodes) and random draw simulation (10,000,000 iterations) for 3-way
overlap (probability of the observed number of barcodes being present in all three populations from the pool of identified barcodes).
Gene Signatures
Leukemic stem cell signature was generated using the upregulated genes identified in leukemic stem cells from previously published
data (Ng et al., 2016). Erythroblast gene signature was generated by selecting the top 200 upregulated genes (adjusted p value<0.05)
from erythroblasts compared to long-term HSCs from previously published data (de Graaf et al., 2016). Myeloblast gene signature
was generated by selecting the overlapping upregulated genes (adjusted p value<0.05, fold change>2) from KLG-E L-MBs
compared to KLG-E L-EBs and KLG-E L-MBs compared to KLG-E L-NMPs. Human M6 AEL was generated by selecting the top
200 up-regulated genes from AEL (FAB: M6) compared to all other AML samples from previously published data (GEO:
GSE14468). BiomaRt was used to interconvert human and mouse gene names in R. Signatures are available upon request.
Single Cell 10x Chromium Analysis
Gene count matrix for each sample was generated using Cell Ranger software (10x Genomics). Sample integration, cluster and gene
expression analysis were performed using Seurat (Butler et al., 2018). tSNE of leukemic stem cell, erythroblast and myeloblast gene
signatures were generated using the AddModuleScore function in Seurat with default settings.
ATAC Sequencing Analysis
Sequences were trimmed using Trim Galore (https://github.com/FelixKrueger/TrimGalore) and mapped to the mm10 murine refer-
ence genome using Bowtie2 (Langmead and Salzberg, 2012). SAMtools was then used to convert sam files to bam files (Li et al.,
2009). Duplicates were then removed using MarkDuplicates function from the Picard tools package (http://broadinstitute.github.
io/picard/). Bam files were subsampled and merged using SAMtools. Peaks were called using MACS2 with default parameters
(Zhang et al., 2008). Regions of chromatin accessibility was quantified as peak counts using the featureCounts function from the Sub-
read package using default parameters. Peaks were annotated using Homer (Heinz et al., 2010). Differential peak analysis was per-
formed using the DESeq2 package. Genes with differentially accessible promoters (p value<0.05; log2 fold change>1.5) were iden-
tified by integrating peaks within 1kb of the transcription start site, and were used to calculate promoter accessibility correlation.
Motif accessibility analysis was performed with ChromVAR using the mouse_pwms_v1 TF motif collection (Schep et al., 2017). Sam-
ple correlation was calculated using the getSampleCorrelation function. Variance of motif accessibility across samples was calcu-
lated using the deviationsScore function and the average deviation score calculated for preleukemia genotypes and leukemia phe-
notypes. Correlation between deviation scores and promoter accessibilities was calculated using linear modelling in R after filtering
for significance (p value<0.005 for motifs, p value<0.05 and Log2Fc>1.5 for promoters).
Mutational Analysis by Whole Exome Sequencing
Somatic variants were called using a custom pipeline. Pre-processing was performed according to GATK best practice. Read
alignment to the mm10 reference genome was performed with the BWA algorithm (v0.7.17; https://arxiv.org/abs/1303.3997), with
corrections with GATK4 BaseRecalibrator (v4.0.5.1) (McKenna et al., 2010) after removal of PCR duplicates with Picard MarkDupli-
cates (v2.18.7). Somatic variant detection was carried out using three variant callers: GATK4Mutect2 (v4.0.5.1; t_lod>=3.5), Strelka2Cancer Cell 37, 690–704.e1–e8, May 11, 2020 e7
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Artefact variants due to DNA oxidation resulting in G to T transversion during library preparation were filtered out using GATK
FilterByOrientationBias. Annotation was performed using Ensembl VEP (v.98) (McLaren et al., 2016). Somatic variants were defined
as the overlap of at least two out of the three variant callers with VAF>5%, with a minimum of 10 reads and filtered to exclude non-
coding and synonymous variants.
DATA AND CODE AVAILABILITY
RNA-sequencing (GEO: GSE121492), ATAC-sequencing (GEO: GSE141812) and 10x RNA-sequencing (GEO: GSE142213) data
have been deposited in GEO under the SuperSeries accession number: GEO: GSE141813. Previously published expression data
used to create the human AELM6 gene signature is available through GEO under GEO: GSE14468. The R code supporting the study
is available from the Lead Contact on request.e8 Cancer Cell 37, 690–704.e1–e8, May 11, 2020
